Boston Scientific (BSX) Gross Profit (2009 - 2026)

Boston Scientific (BSX) has 18 years of Gross Profit data on file, last reported at $3.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 12.59% year-over-year to $3.6 billion; the trailing twelve-month figure through Mar 2026 stood at $14.3 billion (up 18.31% YoY), and the FY2025 full-year result was $13.9 billion, up 20.57% from the prior year.
• Gross Profit retreated to $3.6 billion in Q1 2026, from $3.7 billion in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $3.7 billion in Q4 2025 to a low of $2.1 billion in Q1 2022.
• A 5-year average of $2.8 billion and a median of $2.6 billion in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit climbed 3.57% in 2022 and increased 22.26% in 2025, its largest moves.
• Tracing BSX's Gross Profit over 5 years: stood at $2.2 billion in 2022, then climbed by 15.55% to $2.6 billion in 2023, then rose by 20.01% to $3.1 billion in 2024, then gained by 18.87% to $3.7 billion in 2025, then retreated by 1.77% to $3.6 billion in 2026.
• Business Quant data shows BSX's Gross Profit at $3.6 billion in Q1 2026, $3.7 billion in Q4 2025, and $3.5 billion in Q3 2025.